UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036735
Receipt number R000041855
Scientific Title 13C-caffeine breath test for the identification of single nucleotide polymorphisms associated with caffeine metabolism
Date of disclosure of the study information 2019/05/15
Last modified on 2022/11/18 10:04:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

13C-caffeine breath test for the identification of single nucleotide polymorphisms associated with caffeine metabolism

Acronym

13C-caffeine breath test for the identification of single nucleotide polymorphisms associated with caffeine metabolism

Scientific Title

13C-caffeine breath test for the identification of single nucleotide polymorphisms associated with caffeine metabolism

Scientific Title:Acronym

13C-caffeine breath test for the identification of single nucleotide polymorphisms associated with caffeine metabolism

Region

Japan


Condition

Condition

none

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

We performed 13C-caffeine breath test (CafeBT) to determine whether it can be used to identify SNPs (CYP1A2, aryl-hydrocarbon receptor, adenosine A2A receptor) that are associated with caffeine metabolism.

Basic objectives2

Others

Basic objectives -Others

4 SNPs (rs762551, rs2472297, rs4410790, and rs5751876) in the AUC of the breath 13CO2 to evaluate whether it can be identified.

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

4 SNPs (rs762551, rs2472297, rs4410790, and rs5751876) in the AUC of the breath 13CO2 to evaluate whether it can be identified.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Other

Interventions/Control_1

N-3-methyl-13C caffeine 100mg
caffeine 13C3 (trimethyl-13C3) 100mg
N-1-methyl-13C caffeine 100mg

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

Healthy adults

Key exclusion criteria

none

Target sample size

600


Research contact person

Name of lead principal investigator

1st name YUKIMOTO
Middle name
Last name ISHII

Organization

Nihon University School of Medicine

Division name

Division of Research Planning and Development, Medical Research Support Center

Zip code

173-8610

Address

Ohyaguchi 30-1, Itabashi-ku, Tokyo, Japan

TEL

03-3972-8111

Email

ishii.yukimoto@nihon-u.ac.jp


Public contact

Name of contact person

1st name YUKIMOTO
Middle name
Last name ISHII

Organization

Nihon University School of Medicine

Division name

Division of Research Planning and Development, Medical Research Support Center

Zip code

173-8610

Address

Ohyaguchi 30-1, Itabashi-ku, Tokyo, Japan

TEL

03-3972-8111

Homepage URL


Email

ishii.yukimoto@nihon-u.ac.jp


Sponsor or person

Institute

Division of Research Planning and Development, Medical Research Support Center, Nihon University School of Medicine.

Institute

Department

Personal name



Funding Source

Organization

Division of Research Planning and Development, Medical Research Support Center, Nihon University School of Medicine.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nihon University School of Medicine, Ethics Committee

Address

Ohyaguchi 30-1, Itabashi-ku, Tokyo, Japan

Tel

0339728111

Email

med.kenjimu@nihon-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 05 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2009 Year 08 Month 22 Day

Date of IRB

2017 Year 08 Month 22 Day

Anticipated trial start date

2017 Year 10 Month 31 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry

2023 Year 03 Month 31 Day

Date trial data considered complete

2023 Year 03 Month 31 Day

Date analysis concluded

2023 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2019 Year 05 Month 14 Day

Last modified on

2022 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041855


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name